FDA’s Graham Casts Doubt On Naproxen Cardioprotection, Vioxx Defense
This article was originally published in The Tan Sheet
Executive Summary
Debate during a three-day panel meeting on the safety of COX-2s and NSAIDs appeared to reach a consensus that naproxen carries little to no cardioprotective benefit
You may also be interested in...
Naproxen Cardio Benefit “Not Large Enough” To Back Vioxx Defense – Lancet
Naproxen's perceived cardioprotective benefit demonstrated in studies likely is due to coincidence, according to a recent study published in the Lancet
Reversal Of Fortune? Vioxx Recall Presents Opportunity For NSAID Makers
OTC NSAID manufacturers could be the indirect beneficiaries of Merck's decision to initiate a worldwide recall of its COX-2 inhibitor Vioxx (rofecoxib)
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC